Charles Schwab Investment Management Inc Synthetic Biologics, Inc. Transaction History

Charles Schwab Investment Management Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.9 - $2.9 $257,771 - $393,440	135,669 New	135,669 $29,000
Q2 2021 Aug 16, 2021	SELL	$4.6 - $7.2 $240,639 - $376,653	-52,313 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.0 - $11.7 $261,565 - $612,062	52,313 New	52,313 $36,000

Ticker SYN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,844,100
Market Cap $9.51M
Description
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.